Le Lézard
Classified in: Health, Business
Subjects: LIC, PET, ANW

GRONK (& HIS GOOD BOY RALPHIE) PARTNER WITH ANIVIVE, THE NEXT-GEN ANIMAL HEALTH COMPANY ACCELERATING RESEARCH & DEVELOPMENT AND ACCESS TO CRITICALLY NEEDED NEW PET MEDICINES IN THE U.S.


LOS ANGELES, Feb. 8, 2023 /PRNewswire/ -- Anivive Lifesciences today announced its partnership with 4-Time Super Bowl Champion and 5-Time NFL Pro-Bowler Rob "Gronk" Gronkowski, who is investing in the pet health start-up and raising awareness about the importance of new pet medicines, including a vaccine for Valley Fever.

Gronk and his good boy Ralphie partner with Anivive, the next-gen animal health company

 

Named 2022 Best Animal Health Company in North America by S&P Global, Anivive's mission is to accelerate the development of and access to new, affordable treatments for life-threatening diseases in pets. The company is currently developing an anti-fungal vaccine, which may become the first anti-fungal vaccine ever approved for any species. The application of this vaccine could help more than 30 million dogs who are at risk for Valley Fever ? a systemic, fungal disease impacting humans and animals most commonly in Arizona and throughout the Southwest, although the geographic range is expanding as a result of climate change.

Gronkowski, who played college football for the University of Arizona, has seen the impact of Valley Fever in the region. As the proud pet parent to his French Bulldog Ralphie, he is advocating for pets and their owners to have access to affordable and innovative care that addresses illnesses like these.

"The more I learned about Anivive, the more I fell in love with their mission," said Gronkowski. "I wanted to be a part of saving pets lives with a company that is making treatments that have never been done before. And they are making it affordable for pet owners which is huge! I rarely invest in things, but this is something I am passionate about and really believe in."

"Rob shares our passion to help pets live happy, healthy and longer lives," said Dylan Balsz, Anivive founder & CEO. "We're excited for his support, and proud that we're able to develop and deliver life-saving treatments for overlooked diseases in pets."

For more information visit Anivive Lifesciences and Instagram

About Anivive Lifesciences
Anivive is a pet health company at the intersection of biotech, AI, software, and veterinary medicine. Focusing on three key therapeutic platforms; Fungal, Oncology, and Infectious Disease, our proprietary software platform accelerates the delivery of new, affordable treatments for various life-threatening diseases in pets. For more information, please visit www.anivive.com. 

Press Contacts:
Thomas Wright: [email protected],  +14243134869

Photo - https://mma.prnewswire.com/media/1998867/Gronk_and_his_good_boy_Ralphie.jpg

SOURCE Anivive Lifesciences


These press releases may also interest you

at 21:13
The First Nations of Quebec and Labrador Health and Social Services Commission (FNQLHSSC) is proud of the appointment of Dr. Stanley Vollant, Public Health Physician Advisor for the FNQLHSSC, to the Board of Directors of Santé Québec, the new...

at 20:51
PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced that its U.S. subsidiary, Wincal Biopharm, Inc. ("WincalBio"), gained...

at 20:27
The Monroe Institute, a renowned pioneer in the exploration of human consciousness, and Roxiva Innovations, a leading developer of cutting-edge Audio-Visual Brainwave Entrainment...

at 20:25
Turn Therapeutics, an innovative biotech company, launched its first public investment campaign today to fund clinical trials of its Food and Drug Administration-cleared antimicrobial ointment for two potential new drug indications: moderate to...

at 19:47
Cynata Therapeutics Limited , a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease...

at 19:23
Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license...



News published on and distributed by: